ERBB2 and breast cancer: The association of ZMYND10 promoter methylation and patient clinicopathological features was analyzed, which clearly showed that ZMYND10 methylation was not statistically connected to age, histological type, tumor size, lymph node metastasis, or PR, ER, and HER2 breast cancer patient status (data not shown).